# A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

> **NCT04026412** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 925 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** ipilimumab
- **BIOLOGICAL:** durvalumab

## Key facts

- **NCT ID:** NCT04026412
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-08
- **Primary completion:** 2024-03-22
- **Final completion:** 2024-11-26
- **Target enrollment:** 925 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026412, "A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04026412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*